Featured Publications
National Trends in the Burden of Atrial Fibrillation During Hospital Admissions for Heart Failure
Reinhardt SW, Chouairi F, Miller PE, Clark KAA, Kay B, Fuery M, Guha A, Freeman JV, Ahmad T, Desai NR, Friedman DJ. National Trends in the Burden of Atrial Fibrillation During Hospital Admissions for Heart Failure. Journal Of The American Heart Association 2021, 10: e019412. PMID: 34013736, PMCID: PMC8483517, DOI: 10.1161/jaha.120.019412.Peer-Reviewed Original ResearchConceptsReduced ejection fractionComorbid atrial fibrillationHeart failureAtrial fibrillationEjection fractionHospital mortalityHF hospitalizationBackground Heart failureConclusion Atrial fibrillationWhite individualsNational Inpatient SampleMedian hospital chargesMore comorbiditiesComorbid hypertensionHF admissionsHF outcomesPatient demographicsDiabetes mellitusHospital admissionHospital chargesInpatient SampleVascular diseaseHospitalizationPatientsMortality
2021
Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial
Reinhardt SW, Desai NR, Tang Y, Jones PG, Ader J, Spertus JA. Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial. PLOS ONE 2021, 16: e0256338. PMID: 34411158, PMCID: PMC8376053, DOI: 10.1371/journal.pone.0256338.Peer-Reviewed Original ResearchConceptsAbsolute risk reductionPrior stroke/TIAStroke/TIASystemic embolismAtrial fibrillationMajor bleedingRE-LYOlder patientsLong-Term Anticoagulation Therapy (RE-LY) trialStroke/systemic embolismGood renal functionHigh-risk patientsHistory of diabetesRE-LY trialPatient-level dataShared decision makingMedian followRenal functionHeart failureHeavier patientsMultivariable modelDabigatranIndividual patientsTreatment groupsIndividualized estimates